, efficacy and safety of tralokinumab after 32 and 52weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study
Pezzolo, Elena;Schena, Donatella;Girolomoni, Giampiero;Naldi, Luigi;
2024-01-01
Abstract
, efficacy and safety of tralokinumab after 32 and 52weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pezzolo tralo JEADV 2024.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
247.44 kB
Formato
Adobe PDF
|
247.44 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
